Natco had signed a licence and supply agreement on Tuesday with Mylan for its glatiramer acetate pre-filled syringes, a generic version of Teva's CopaxoneR, which is used to treat multiple sclerosis.
The agreement grants Mylan exclusive distribution rights in the US and all major markets in Europe, Australia, New Zealand, Japan and Canada and includes an option to expand into additional territories.
Natco has commercialised its glatiramer acetate product in India and the Ukaraine.
"We are happy for this agreement with Mylan," Natco chief operating officer and director Rajeev Nannapaneni. Apart from its expertise regulatory applications, Mylan's presence in 90 countries and a broad portfolio would enable the Natco's glatiramer acetate product to be available to a wide patient base, he said.
Natco has US Food and Drug Administration (US FDA)-approved manufacturing facilities both for active pharmaceutical ingredients (APIs) as well as finished dosage pharmaceutical formulations, according to a release on Tuesday.
